CoFlo Medical Announces $6M Seed for Drug Delivery
The needle gets a vote in drug development. CoFlo Medical, a San Francisco drug-delivery company, is building equipment that could give pharmaceutical developers more freedom in the formulations they choose. CEO and cofounder Simon Rufer announced a $6M Seed round on November 19, 2026, and J2 Ventures confirms it is leading the financing.
CoFlo's core annular flow technology surrounds a viscous medicine with a lower-viscosity fluid as both pass through the needle. That arrangement addresses a practical constraint on concentrated injectable medicines: a smaller dose volume can arrive with a liquid that is harder to push. For developers and, eventually, patients, the commercial significance lies in the treatment options a workable delivery method could make possible.
A Seed round following years of research
Rufer's original funding announcement identifies the round as $6M Seed and names J2 Ventures as a backer. J2 Ventures' own announcement confirms the lead-investor role and describes CoFlo as an MIT spinout. The current disclosures do not specify a valuation, the full investor syndicate or a detailed allocation of the proceeds.
The financing record requires some care. A 2025 SEC Form D recorded a $6M offering with $500K sold at that point. Rufer's November 2026 announcement supplies the current Seed-round figure; the earlier filing supplies a historical view of fundraising in progress. Adding the two figures would manufacture a lifetime funding total the sources have not established.
CoFlo's three cofounders bring different parts of the underlying work into the company. Rufer is CEO, Vishnu Jayaprakash is CBO, and MIT professor Kripa Varanasi is chairman, according to the current company website. MIT reported their founding roles when CoFlo won its $100K entrepreneurship competition in May 2025. That prize recognized the venture before the latest financing announcement, without resolving the separate questions of product commercialization or clinical adoption.
Why the liquid around the drug matters
Core annular flow changes the interaction between a drug and the inside of a needle. The viscous formulation travels through the center, while a thinner surrounding fluid separates it from the wall. CoFlo's technical FAQ explains that the sheath must be compatible with the medicine and is delivered along with it. Depending on the formulation, the sheath can include the drug's own buffer solution.
The research has a history that predates the current funding. A 2020 paper in Advanced Healthcare Materials, with Jayaprakash and Varanasi among its authors, reported improved injectability using coaxial lubrication. Its authors demonstrated up to a sevenfold reduction in injection force under the conditions tested, providing an early scientific basis for the approach.
Later company-authored work describes further development. In a September 2026 technical article, Rufer and Pratik Mishra reported a 100-fold force reduction in specified demonstrations, including a viscous mimic solution. Those experiments have their own formulations, equipment and conditions. Reading them as universal claims about every medicine or as clinical results would run far ahead of the evidence. What they establish for the business discussion is a developing engineering approach with published experimental work behind it.
The pharmaceutical partner is part of the product
CoFlo lists Gen One, Double Barrel and CO-AXL hub configurations on its website. The variations give developers different ways to supply the sheath fluid and combine it with the drug stream. A platform with several configurations can enter different development discussions, but the useful configuration still depends on the medicine, container and intended administration setting.
That creates a commercial relationship more involved than selling a clever syringe attachment. A pharma developer has already made decisions about the molecule, its concentration and the dose. Introducing a delivery method gives the development team another set of choices to evaluate together. CoFlo's opportunity sits inside that process, where an improvement in injection mechanics has to become something the partner can incorporate into its own program.
Rufer says CoFlo is working with 5 of the 20 largest pharmaceutical companies on next-generation therapies. The companies remain unnamed, and the figure is a founder-reported measure of development activity. Public information does not establish contract values or commercial product revenue. The relationships nevertheless help explain the audience for the platform: organizations capable of carrying a medicine and its delivery system through the work between an experiment and a treatment.
From formulation choices to a patient's day
CoFlo and J2 describe an ambition to make suitable therapies easier to administer, potentially moving some treatments from lengthy infusions toward injections in doctors' offices or patients' homes. Cancer and autoimmune conditions are among the areas Rufer names. That is the intended direction of development, rather than evidence that CoFlo's platform is already approved for those uses across those diseases.
The wider opportunity is easy to understand without attaching a speculative market-size number. A therapy's place in a patient's life includes the setting, duration and practical burden of administration. An engineering change that expands delivery options could eventually affect those decisions, while the specific medicine and its development pathway determine which options become available.
For J2 Ventures, leading the Seed round places an investment behind the team working on that connection. For Rufer, Jayaprakash and Varanasi, the financing accompanies the move from explaining a fluid phenomenon to helping pharmaceutical partners use it. The next development conversations will concern particular formulations, particular devices and the people who would ultimately have to use them. CoFlo's place in those conversations is where the promise of a shorter treatment visit begins to acquire a practical shape.
Biotech funding, last 30 days
DevCuration's funding database tracked 18 Biotech rounds totaling $4.4B in disclosed capital over the past 30 days. Recent deals we covered:
- Onward Therapeutics Discloses $28M Series B for OncologySeries B · $28M · Nov 20
- Johnson & Johnson Agrees to $2.2B Ollin Biosciences BuyoutM&A · $2.2B upfront · Nov 17
- Seawolf Therapeutics Raises $100M in Seed and Series ASeed and Series A · $100M · Nov 17
- Sofinnova Partners Closes $815M Crossover II FundFund Final Close · $815M · Nov 16
- Neurosterix Raises $105M for Schizophrenia Phase 2 PlansSeries B · $105M · Nov 14
Frequently Asked Questions
Why can a more concentrated medicine be harder to inject?
Concentration can increase a formulation's viscosity, raising the force required to move it through a needle. CoFlo is developing core annular flow devices that surround the drug with a compatible lower-viscosity fluid to reduce that resistance.
Does core annular flow change the drug formulation?
CoFlo describes a delivery approach that places a separate sheath fluid around the drug inside the needle. The sheath can use a compatible fluid such as the drug's own buffer, but compatibility and the complete delivery configuration still need evaluation for the particular medicine.
What do CoFlo's pharmaceutical relationships establish?
CEO Simon Rufer says CoFlo works with 5 of the 20 largest pharmaceutical companies on next-generation therapies. The partners are unnamed, so the statement supports attributed development activity rather than a claim about disclosed revenue or approved products.
Is CoFlo's platform already approved for broad home administration?
The reviewed sources describe home administration as a development ambition for suitable therapies. They do not establish broad regulatory approval or clinical outcomes across the cancer and autoimmune treatments discussed.
How should the 2025 SEC filing be compared with the $6M Seed announcement?
The 2025 filing reported $500K sold toward a $6M offering at that time. The November 19, 2026 founder announcement reports a $6M Seed round; the figures should not be added into a lifetime total without further evidence.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved